Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placeb
-
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
-
Imbria Pharmaceuticals Announces First Patient Randomized in FORTITUDE-HCM Phase 2b Clinical Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
-
For the Second Consecutive Year, Provident Bank Announces $50,000 in Grants to 6 Non-Profit Organizations
-
Aemetis Reports Third Quarter 2025 Financial Results
-
Feed a Family of 10 for Under $40 this Thanksgiving: Stop & Shop Introduces One of the Season’s Best Dinner Deals
-
*MEDIA ALERT* Verizon and David Beckham Launch First-Ever "Golden Ticket" Sweepstakes for FIFA World Cup 26™
-
Sironax Announces Three Abstracts Selected for Presentation at Neuroscience 2025
-
Evotrex Exits Stealth with $16 Million Pre-A to Debut the World’s First Power-Generating RV Trailer at CES 2026
-
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015
-
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
-
Enphase Energy IQ8 Microinverters Power Solar Projects at Gas Stations Worldwide
-
Zscaler to Host First Quarter Fiscal Year 2026 Earnings Conference Call
-
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansio
-
HPQ CEO Applauds and Comments on Canada’s New Federal Budget and Its Positive Impact on HPQ’s Technology Portfolio
-
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
-
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates
-
Melco Announces Unaudited Third Quarter 2025 Earnings
-
Skyworks Introduces New Programmable Bulk Acoustic Wave Clocks for 5G, 6G, and Data Center Applications
-
Form 8.3 - IDOX plc - Octopus Investments
-
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
-
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)
-
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
-
Asure Software Sets November and December 2025 Investor Conference Schedule
-
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
-
*MEDIA ALERT* Verizon and David Beckham Launch First-Ever "Golden Ticket" Sweepstakes for FIFA World Cup 26™
-
SunCar’s Investment in its AI Technology Development Center Driving Strong Premium Sales for its EV Partners
-
GraniteShares Announces Weekly Distributions for its YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, AMYY, TQQY, AZYY, YSPY, MTYY, PLYY, HOYY, SMYY, BBYY, FBYY, IOYY and MAAY
-
SharpLink to Host Third Quarter 2025 Financial Results Conference Call and Webcast on November 13, 2025 at 8:30 A.M. E.T.
-
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
-
LiveOne (Nasdaq: LVO) to Announce Its Second Quarter Fiscal Year 2026 Financial Results and Host Investor Webcast on November 12, 2025, at 10:00 am Eastern Time (7:00 am Pacific Time)
-
LM Funding Announces Third Quarter 2025 Earnings Call for November 14, 2025
-
Workhorse Group Reminds Shareholders to Vote Today FOR All Proposals
-
Locafy Reports Strong Commercial Momentum Going into CY 2026
-
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
-
Healthcare Minus the Headache: RokketMed, A Solution to Finding the Care That Counts
-
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
-
Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia
-
Route 92 Medical Appoints Medtech Industry Leader Pat Mackin to its Board of Directors
-
Solmate Infrastructure (SLMT) Launches the UAE’s First Performant Solana Validator, Announces Infrastructure Flywheel™ Including Planned RPC and Colocation Services
-
Ascent Solar Technologies and CisLunar Industries Enter Teaming Agreement to Bring Power Solutions that Lengthen Missions to U.S. Space Market
-
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
-
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
-
BitFuFu Announces Sponsorship of Mining Disrupt 2025 in Dallas
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Jamf Holding Corp. (Nasdaq – JAMF), CSG Systems International, Inc. (Nasdaq – CSGS), Olympic Steel, Inc. (N
-
Dentsply Sirona Reports Third Quarter 2025 Results
-
Webinar to Explore Solutions for Sustainable Energy and Technology to Power a Resilient Economy
-
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
-
Nanox Collaborates with Leading Czech Medical Imaging Distributor EXRAY to Expand European Footprint
-
Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET

